<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>HISTORY AND CLINICAL FINDINGS: A 51-year-old female patient suffered from recurrent <z:hpo ids='HP_0002140'>ischemic strokes</z:hpo> and venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> although treated with ASS and <z:chebi fb="0" ids="50438">phenprocoumon</z:chebi>, which mainly occurred after diagnosis and treatment of an invasive-ductal mamma <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The severely ill patient presented with right-sided <z:hpo ids='HP_0001269'>hemiparesis</z:hpo> and <z:hpo ids='HP_0001260'>dysarthria</z:hpo>, a swollen leg, a painful necrotic-ulcerative lesion at the left-lateral ankle and a systolic heart murmur </plain></SENT>
<SENT sid="2" pm="."><plain>INVESTIGATIONS: Laboratory data revealed a <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> of 8,4 g/dl, a leucocyte count of 3,1 x 10 (9)/l and a platelet count of 87 x 10 (9)/l </plain></SENT>
<SENT sid="3" pm="."><plain>C-reactive protein, ESR and plasma fibrinogen were markedly increased </plain></SENT>
<SENT sid="4" pm="."><plain>Levels of antinuclear, IgG-anticardiolipin and anti-<z:chebi fb="0" ids="4705">doublestranded-DNA</z:chebi> antibodies were excessively elevated </plain></SENT>
<SENT sid="5" pm="."><plain>A test for <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> was strongly positive </plain></SENT>
<SENT sid="6" pm="."><plain>Sonographic examinations showed <z:hpo ids='HP_0002625'>deep vein thrombosis</z:hpo> and significant <z:hpo ids='HP_0001653'>mitral valve regurgitation</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Suspected <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> was demonstrated by CT scan </plain></SENT>
<SENT sid="8" pm="."><plain>We diagnosed <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> with secondary <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome (APAS) </plain></SENT>
<SENT sid="9" pm="."><plain>TREATMENT AND COURSE: <z:chebi fb="0" ids="50438">Phenprocoumon</z:chebi> was stopped and full-dose anticoagulation with low-molecular-weight <z:chebi fb="5" ids="28304">heparin</z:chebi> initiated </plain></SENT>
<SENT sid="10" pm="."><plain>Additional immunosuppressive therapy consisted of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, azathioprin and <z:chebi fb="0" ids="8382">prednisone</z:chebi> resulting in prevention of further <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> and significant improvement of clinical symptoms </plain></SENT>
<SENT sid="11" pm="."><plain>The observed severe interference of LA with the prothrombin time after cessation of <z:chebi fb="0" ids="50438">phenprocoumon</z:chebi> (INR 3,6; FII activity 81 %) suggested that the effect of oral anticoagulation had been overestimated in the past </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: APAS may present as an <z:hpo ids='HP_0011009'>acute</z:hpo> and life-threatening disorder </plain></SENT>
<SENT sid="13" pm="."><plain>In this case interdisciplinary co-operation and a highly individualised treatment strategy are mandatory </plain></SENT>
</text></document>